Spero therapeutics announces first quarter 2024 operating results and provides a business update

Cambridge, mass., may 15, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced financial and operational results for the quarter ended march 31, 2024.
SPRO Ratings Summary
SPRO Quant Ranking